Cargando…
Monoclonal antibodies capable of binding SARS‐CoV‐2 spike protein receptor‐binding motif specifically prevent GM‐CSF induction
A severe acute respiratory syndrome (SARS)‐like coronavirus 2 (SARS‐CoV‐2) has recently caused a pandemic COVID‐19 disease that infected approximately 94 million and killed more than 2,000,000 people worldwide. Like the SARS‐CoV, SARS‐CoV‐2 also employs a receptor‐binding motif (RBM) of its envelope...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251270/ https://www.ncbi.nlm.nih.gov/pubmed/33759207 http://dx.doi.org/10.1002/JLB.3COVCRA0920-628RR |
_version_ | 1783717089140277248 |
---|---|
author | Qiang, Xiaoling Zhu, Shu Li, Jianhua Chen, Weiqiang Yang, Huan Wang, Ping Tracey, Kevin J. Wang, Haichao |
author_facet | Qiang, Xiaoling Zhu, Shu Li, Jianhua Chen, Weiqiang Yang, Huan Wang, Ping Tracey, Kevin J. Wang, Haichao |
author_sort | Qiang, Xiaoling |
collection | PubMed |
description | A severe acute respiratory syndrome (SARS)‐like coronavirus 2 (SARS‐CoV‐2) has recently caused a pandemic COVID‐19 disease that infected approximately 94 million and killed more than 2,000,000 people worldwide. Like the SARS‐CoV, SARS‐CoV‐2 also employs a receptor‐binding motif (RBM) of its envelope spike protein for binding the host angiotensin‐converting enzyme 2 (ACE2) to gain viral entry. Currently, extensive efforts are being made to produce vaccines against a surface fragment of a SARS‐CoV‐2, such as the spike protein, in order to boost protective antibodies that can inhibit virus‐ACE2 interaction to prevent viral entry. It was previously unknown how spike protein‐targeting antibodies would affect innate inflammatory responses to SARS‐CoV‐2 infections. Here we generated a highly purified recombinant protein corresponding to the RBM of SARS‐CoV‐2, and used it to screen for cross‐reactive monoclonal antibodies (mAbs). We found two RBM‐binding mAbs that competitively inhibited its interaction with human ACE2, and specifically blocked the RBM‐induced GM‐CSF secretion in both human peripheral blood mononuclear cells and murine macrophage cultures. Our findings have suggested a possible strategy to prevent SARS‐CoV‐2‐elicited “cytokine storm,” and revealed a potentially anti‐inflammatory and protective mechanism for SARS‐CoV‐2 spike‐based vaccines. |
format | Online Article Text |
id | pubmed-8251270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82512702021-07-02 Monoclonal antibodies capable of binding SARS‐CoV‐2 spike protein receptor‐binding motif specifically prevent GM‐CSF induction Qiang, Xiaoling Zhu, Shu Li, Jianhua Chen, Weiqiang Yang, Huan Wang, Ping Tracey, Kevin J. Wang, Haichao J Leukoc Biol Covid‐19 Initiaitve A severe acute respiratory syndrome (SARS)‐like coronavirus 2 (SARS‐CoV‐2) has recently caused a pandemic COVID‐19 disease that infected approximately 94 million and killed more than 2,000,000 people worldwide. Like the SARS‐CoV, SARS‐CoV‐2 also employs a receptor‐binding motif (RBM) of its envelope spike protein for binding the host angiotensin‐converting enzyme 2 (ACE2) to gain viral entry. Currently, extensive efforts are being made to produce vaccines against a surface fragment of a SARS‐CoV‐2, such as the spike protein, in order to boost protective antibodies that can inhibit virus‐ACE2 interaction to prevent viral entry. It was previously unknown how spike protein‐targeting antibodies would affect innate inflammatory responses to SARS‐CoV‐2 infections. Here we generated a highly purified recombinant protein corresponding to the RBM of SARS‐CoV‐2, and used it to screen for cross‐reactive monoclonal antibodies (mAbs). We found two RBM‐binding mAbs that competitively inhibited its interaction with human ACE2, and specifically blocked the RBM‐induced GM‐CSF secretion in both human peripheral blood mononuclear cells and murine macrophage cultures. Our findings have suggested a possible strategy to prevent SARS‐CoV‐2‐elicited “cytokine storm,” and revealed a potentially anti‐inflammatory and protective mechanism for SARS‐CoV‐2 spike‐based vaccines. John Wiley and Sons Inc. 2021-03-24 2022-01 /pmc/articles/PMC8251270/ /pubmed/33759207 http://dx.doi.org/10.1002/JLB.3COVCRA0920-628RR Text en © 2021 The Authors. Journal of Leukocyte Biology published by Wiley Periodicals LLC on behalf of Society for Leukocyte Biology https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Covid‐19 Initiaitve Qiang, Xiaoling Zhu, Shu Li, Jianhua Chen, Weiqiang Yang, Huan Wang, Ping Tracey, Kevin J. Wang, Haichao Monoclonal antibodies capable of binding SARS‐CoV‐2 spike protein receptor‐binding motif specifically prevent GM‐CSF induction |
title | Monoclonal antibodies capable of binding SARS‐CoV‐2 spike protein receptor‐binding motif specifically prevent GM‐CSF induction |
title_full | Monoclonal antibodies capable of binding SARS‐CoV‐2 spike protein receptor‐binding motif specifically prevent GM‐CSF induction |
title_fullStr | Monoclonal antibodies capable of binding SARS‐CoV‐2 spike protein receptor‐binding motif specifically prevent GM‐CSF induction |
title_full_unstemmed | Monoclonal antibodies capable of binding SARS‐CoV‐2 spike protein receptor‐binding motif specifically prevent GM‐CSF induction |
title_short | Monoclonal antibodies capable of binding SARS‐CoV‐2 spike protein receptor‐binding motif specifically prevent GM‐CSF induction |
title_sort | monoclonal antibodies capable of binding sars‐cov‐2 spike protein receptor‐binding motif specifically prevent gm‐csf induction |
topic | Covid‐19 Initiaitve |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251270/ https://www.ncbi.nlm.nih.gov/pubmed/33759207 http://dx.doi.org/10.1002/JLB.3COVCRA0920-628RR |
work_keys_str_mv | AT qiangxiaoling monoclonalantibodiescapableofbindingsarscov2spikeproteinreceptorbindingmotifspecificallypreventgmcsfinduction AT zhushu monoclonalantibodiescapableofbindingsarscov2spikeproteinreceptorbindingmotifspecificallypreventgmcsfinduction AT lijianhua monoclonalantibodiescapableofbindingsarscov2spikeproteinreceptorbindingmotifspecificallypreventgmcsfinduction AT chenweiqiang monoclonalantibodiescapableofbindingsarscov2spikeproteinreceptorbindingmotifspecificallypreventgmcsfinduction AT yanghuan monoclonalantibodiescapableofbindingsarscov2spikeproteinreceptorbindingmotifspecificallypreventgmcsfinduction AT wangping monoclonalantibodiescapableofbindingsarscov2spikeproteinreceptorbindingmotifspecificallypreventgmcsfinduction AT traceykevinj monoclonalantibodiescapableofbindingsarscov2spikeproteinreceptorbindingmotifspecificallypreventgmcsfinduction AT wanghaichao monoclonalantibodiescapableofbindingsarscov2spikeproteinreceptorbindingmotifspecificallypreventgmcsfinduction |